Goldman Sachs
ONC

Goldman Sachs’s BeOne Medicines Ltd ONC Stock Holding History

Goldman Sachs’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-85,000
Closed -$24.3M – 5754
2020
Q3 		$24.3M Buy
+85,000
New +$20M 0.01% 1582
2020
Q1 		– Sell
-25,500
Closed -$4.23M – 5613
2019
Q4 		$4.23M Buy
+25,500
New +$4.24M ﹤0.01% 3084

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs's ONC Position: Q2 2026 in Review

Goldman Sachs increased its BeOne Medicines Ltd (ONC) stake by 63% in Q2 2026, buying an estimated $18M and bringing the position to 157,701 shares worth $44.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1903.

Goldman Sachs first reported a position in ONC in Q1 2016 and has held it in 41 quarters since. The position peaked at $141M in Q1 2021. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Goldman Sachs held 157,701 shares of BeOne Medicines Ltd worth $44.9M as of Q2 2026.
  • Goldman Sachs bought 61,024 BeOne Medicines Ltd shares in Q2 2026, an estimated $18M.
  • BeOne Medicines Ltd made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1903 holding.
  • Goldman Sachs first reported a position in BeOne Medicines Ltd in Q1 2016 and has held it in 41 quarters since.
  • Goldman Sachs's BeOne Medicines Ltd position peaked at $141M in Q1 2021.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.